GI Dynamics (ASX:GID) said last week in a regulatory filing that it fired chief medical officer Dr. David Maggs “for cause.” The Lexington, Mass.-based medical device company did not otherwise elaborate on the reason for Maggs’s departure, which was effective June 18, according to the filing. Maggs joined GI Dynamics in April 2013 to oversee the clinical […]
second-sight-medical
ConvaTec makes interim chief Moraviec CEO | Personnel Moves
ConvaTec, which is rumored to be exploring a sale, said yesterday that it made its interim CEO, former EMEA president Paul Moraviec, to be its new permanent CEO.
Luxembourg-based ConvaTec, which is owned by private equity firms Avista Capital Partners and Nordic Capital, tapped Moraviec to lead its business in Europe, the Middle East and Africa in 2009.
Second Sight logs milestone in quest to ‘cure’ blindness
‘Bionic eye’ maker Second Sight Medical slumps on Q4 report
Report: BiOM may file for IPO in 2016
Personal bionics maker BiOM may eventually take its case to the public markets, eyeing a potential initial public offering, according to a report in the Boston Business Journal.
DeviceTalks flashback: Second Sight Medical’s CEO Robert Greenberg on the pursuit of the “Bionic Eye”
Speculation mounts about possible Stryker offer for Smith & Nephew | Medtech Wall Street news for the week of December 1, 2014
Second Sight Medical’s IPO grosses $36m
Second Sight CEO Greenberg: Next-gen ‘bionic eye’ could treat nearly all forms of blindness
Eyesight to the blind: Second Sight prices $32m IPO
Second Sight Medical said today that it expects to reap nearly $32 million today when its shares debut on the public market.